How do the results of LIBRETTO-432 shape the potential role of adjuvant selpercatinib in patients with early-stage RET fusion-positive NSCLC?
How would you counsel stage IB patients?
Any concerns regarding the rate of grade 3 events and drug discontinuation in the treatment arm?
Community PollStarted
Will you be offering adjuvant selpercatinib per LIBRETTO-432 to patients with RET-fusion driven Stage IB or II lung adenocarcinoma?
68 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center
Answered on
The results of LIBRETTO-432 provide strong evidence to consider selpercatinib for patients with stage II-IIIA RET fusion-positive NSCLC, with a highly significant HR of 0.172 (0.058-0.59) for this cohort. When thinking about stage IB (tumors 3- 4 cm, T2b), most of these patients were not included in...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Roswell Park Comprehensive Cancer Center
Answered on · Updated on
LIBRETTO-432 is the 3rd RCT to provide evidence supporting the role of adjuvant targeted therapy in oncogenically driven NSCLC. Given the low incidence of RET translocation, this study defined definitive therapy for stage IB-IIIA disease as either surgery or radiotherapy, with primary analysis of EF...
Join for free or sign in to see the full answer